首页> 外国专利> Treatment and prevention of endometrial disease, e.g. endometriosis or carcinoma, by inhibiting endocrine gland vascular endothelial growth factor, also diagnosis

Treatment and prevention of endometrial disease, e.g. endometriosis or carcinoma, by inhibiting endocrine gland vascular endothelial growth factor, also diagnosis

机译:子宫内膜疾病的治疗和预防子宫内膜异位症或癌,通过抑制内分泌腺血管内皮生长因子,也可诊断

摘要

A composition that contains, as active agent (A), an endocrine gland vascular endothelial growth factor (EG-VEGF) nucleic acid, polypeptide or antisense nucleic acid, antibody against EG-VEGF or its receptor (EG-VEGF-R), or EG-VEGF-R antisense nucleic acid, is useful for the treatment or prevention of endometrial diseases : Independent claims are also included for the following: (1) method for detecting uterine receptivity by determining the amount of EG-VEGF polypeptide and/or nucleic acid, using the new composition; or (2) test system for identifying antagonists (B) of EG-VEGF-R. ACTIVITY : Cytostatic; Gynecological. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibiting activity or expression of endocrine gland vascular endothelial growth factor (EG-VEGF) , which is overexpressed in patients with endometriosis; gene therapy.
机译:包含内分泌腺血管内皮生长因子(EG-VEGF)核酸,多肽或反义核酸,抗EG-VEGF或其受体的抗体(EG-VEGF-R)或作为活性剂(A)的组合物EG-VEGF-R反义核酸可用于治疗或预防子宫内膜疾病:还包括以下方面的独立权利要求:(1)通过确定EG-VEGF多肽和/或核酸的量来检测子宫接受性的方法酸,使用新的成分;或(2)鉴定EG-VEGF-R拮抗剂(B)的测试系统。活动:细胞抑制;妇科没有提供这些活动的测试详细信息。作用机理:内异症患者过度表达的抑制活性或内分泌腺血管内皮生长因子(EG-VEGF)的表达;基因治疗。

著录项

  • 公开/公告号DE10229379A1

    专利类型

  • 公开/公告日2004-01-29

    原文格式PDF

  • 申请/专利权人 SCHERING AG;

    申请/专利号DE2002129379

  • 申请日2002-06-26

  • 分类号A61K39/395;A61K38/17;A61K31/711;

  • 国家 DE

  • 入库时间 2022-08-21 22:44:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号